Efficacy and safety of tozorakimab in moderate‐to‐severe atopic dermatitis: A Phase 2a randomized controlled trial (<scp>FRONTIER</scp>‐2)
FRONTIER-2 did not show a statistically significant difference in the primary endpoint for tozorakimab compared with placebo. However, numerical increases in responder rates were observed.
Authors
- Richard T. Smith (ORCID: https://orcid.org/0000-0003-2142-9802)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- E. Jiménez (ORCID: https://orcid.org/0000-0002-5526-6637)
- R. Moate
- MG Belvisi
- Marami Mustapa (ORCID: https://orcid.org/0000-0002-7697-9142)
- Anne‐Maree Kelly (ORCID: https://orcid.org/0000-0002-4655-5023)
- C. Kell
- M. W. Sadiq
- M. Gavala
- F. Reid
- Hitesh Pandya (ORCID: https://orcid.org/0000-0003-0514-2529)
- Rong Chen (ORCID: https://orcid.org/0000-0001-8751-9590)
- Alejhandra Lei
Institutions
- AstraZeneca (United Kingdom) (GB)
- George Washington University (US)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
Publication Details
- Journal
- Journal of the European Academy of Dermatology and Venereology
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1111/jdv.20388
- Citations
- 7
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.74
Funders
- Pfizer
- AstraZeneca
- Incyte
- Galderma